NX-5948 Clinical Trials
3 recruitingDrug
Phase 12Phase 21
Showing 1–3 of 3 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled18 locationsNCT07221500
Recruiting
Phase 1
Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Healthy Volunteer
Nurix Therapeutics, Inc.18 enrolled1 locationNCT06717269